Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Epetraborole - Pfizer

Drug Profile

Epetraborole - Pfizer

Alternative Names: AN-3365; AN2-501971; BRII-658; GSK '052; GSK-052; GSK-2251052

Latest Information Update: 22 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Anacor Pharmaceuticals
  • Developer AN2 Therapeutics; Anacor Pharmaceuticals; GlaxoSmithKline
  • Class 2 ring heterocyclic compounds; Anti-infectives; Antibacterials; Benzene derivatives; Organic boron compounds; Small molecules
  • Mechanism of Action Leucyl-tRNA synthetase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Nontuberculous mycobacterium infections
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Nontuberculous mycobacterium infections
  • Preclinical Melioidosis
  • Suspended Gram-negative infections
  • Discontinued Intra-abdominal infections; Urinary tract infections

Most Recent Events

  • 13 Feb 2024 AN2 Therapeutics pause enrolment in a phase III part of phase II/III trial for Nontuberculous mycobacterium infections (Treatment-resistant) in USA, Australia, Japan, South Korea (NCT05327803)
  • 27 Nov 2023 Antimicrobial data from preclinical studies in Mycobacterium infections presented at the IDWeek-2023 (IDW-2023)
  • 11 Oct 2023 Adverse events and pharmacokinetics data from a phase I trial in Nontuberculous mycobacterium infections presented at the IDWeek 2023 (IDW-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top